Endocrinology ยท Naas, Co. Kildare

Expert Diabetes Management

Specialist consultant-led care for Type 1 and Type 2 diabetes, including HbA1c optimisation, insulin review, continuous glucose monitoring, and access to the latest evidence-based therapies.

What is Diabetes?

Diabetes mellitus is a chronic metabolic condition characterised by elevated blood glucose levels, resulting from defects in insulin secretion, insulin action, or both. It is one of the most common long-term conditions managed in specialist endocrinology practice.

Type 1 diabetes is an autoimmune condition in which the immune system destroys insulin-producing beta cells in the pancreas. It typically presents in childhood or early adulthood and requires lifelong insulin therapy.

Type 2 diabetes accounts for the majority of diabetes cases and involves a combination of insulin resistance and progressive beta-cell dysfunction. It is strongly associated with excess weight, physical inactivity, and family history, though it can occur in lean individuals.

This page is for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional for assessment and management of diabetes.

Recognising the Signs

Symptoms of uncontrolled diabetes can include:

  • Excessive thirst (polydipsia)
  • Frequent urination (polyuria)
  • Unexplained weight loss
  • Fatigue and low energy
  • Blurred vision
  • Slow wound healing
  • Recurrent infections
  • Tingling or numbness in feet

Many people with Type 2 diabetes have no symptoms at diagnosis, which is why routine screening is important. If you are experiencing any of the above, please speak with your GP.

How We Can Help

Dr Syed Kazmi provides consultant-level diabetes management, offering a comprehensive assessment of glucose control, complications risk, and treatment optimisation.

๐Ÿ“Š

HbA1c Optimisation

Detailed review of glycaemic control with personalised HbA1c targets. We balance optimal glucose management with quality of life, avoiding unnecessary hypoglycaemia.

๐Ÿ’‰

Insulin Therapy Review

Assessment and adjustment of insulin regimens for both Type 1 and Type 2 diabetes, including basal-bolus regimens, pre-mixed insulins, and insulin pump considerations.

๐Ÿ“ก

Continuous Glucose Monitoring

Review and interpretation of CGM and flash glucose monitoring (FreeStyle Libre) data. Guidance on time-in-range targets and using technology to improve outcomes.

๐Ÿ’Š

Modern Diabetes Therapies

Access to the latest evidence-based treatments including GLP-1 receptor agonists and SGLT-2 inhibitors, with careful selection based on individual risk profiles.

๐Ÿ”ฌ

Complication Screening

Assessment for microvascular and macrovascular complications including nephropathy, neuropathy, and retinopathy risk stratification.

โš–๏ธ

Cardiometabolic Risk

Integrated review of cardiovascular risk factors including blood pressure, lipids, and weight, alongside glucose management for comprehensive metabolic care.

Important notice regarding GLP-1 receptor agonists: Medications such as semaglutide and liraglutide are prescription-only medicines regulated by the Health Products Regulatory Authority (HPRA) in Ireland. They must be prescribed by a qualified clinician following a thorough medical assessment and are not suitable for everyone. The information on this page is educational only and does not constitute a recommendation or endorsement for any specific medication.

Your Consultation

A diabetes consultation at our clinic typically includes a detailed clinical history review, assessment of current blood glucose control and HbA1c trends, medication review, and discussion of lifestyle factors. Where appropriate, we may arrange additional investigations including renal function, lipid profile, and specialist referrals.

We work collaboratively with your GP and any other healthcare professionals involved in your care. A detailed clinic letter is sent to your referring physician following each consultation.

Our clinic is led by Dr Syed Kashif Hussain Kazmi, Consultant Endocrinologist (IMC: 213626), with dedicated experience in diabetes management across a wide spectrum of complexity.

Frequently Asked Questions

For most adults with Type 2 diabetes, an HbA1c of 48โ€“53 mmol/mol (6.5โ€“7.0%) is considered well-controlled. However, targets are individualised โ€” younger patients with few comorbidities may aim lower, while older patients or those with recurrent hypoglycaemia may have a higher target set. For Type 1 diabetes, a target below 48 mmol/mol is often recommended where safely achievable. Your consultant will discuss the most appropriate target for you.
You should consider specialist review if your HbA1c remains above target despite treatment changes, if you are experiencing frequent hypoglycaemia, if you require insulin initiation or complex regimen adjustment, if you have significant complications or comorbidities, or if your GP feels a specialist opinion would benefit your management. A referral from your GP is the standard pathway.
Yes. Evidence from studies such as the DiRECT trial shows that significant weight loss โ€” particularly through structured low-calorie dietary programmes โ€” can lead to remission of Type 2 diabetes, defined as HbA1c below 48 mmol/mol for at least three months without glucose-lowering medications. Remission is most achievable in those with a shorter duration of diabetes and significant weight to lose. It requires sustained lifestyle changes and ongoing monitoring, and is not a cure โ€” the underlying predisposition to Type 2 diabetes remains.
GLP-1 receptor agonists are a class of injectable diabetes medications that mimic the action of a naturally occurring gut hormone called glucagon-like peptide-1. They lower blood glucose by stimulating insulin release in response to meals, suppressing glucagon, slowing gastric emptying, and reducing appetite. Some agents in this class have demonstrated significant cardiovascular and renal benefits in large clinical trials. They are prescription-only medicines and their suitability is determined by a clinician following a full assessment. Educational information only โ€” this does not constitute medical advice or a prescribing recommendation.
Insulin is sometimes required in Type 2 diabetes when oral and injectable non-insulin agents are no longer sufficient to maintain adequate glucose control, when there is significant beta-cell failure, during acute illness or surgery, in pregnancy, or when other medications are contraindicated. The decision to commence insulin is based on a full clinical assessment, and there are many modern options including once-daily basal insulins that can be straightforward to manage.

Ready to Take Control of Your Diabetes?

Book a private consultation with Dr Kazmi, Consultant Endocrinologist, at our Naas clinic. Self-referral welcome. GP referral preferred.

Book an Appointment GP Referral Information